Key Highlights
- Acurx Pharmaceuticals shares climbed more than 218% during the week following the announcement of a clinical trial for ibezapolstat, its primary antibiotic candidate.
- Phase 2 trials demonstrated a 96% cure rate for C. difficile infection (CDI), with cured patients experiencing zero recurrences.
- A 20-patient open-label pilot trial targeting recurrent CDI will begin, serving as a foundation for the planned Phase 3 registration trial.
- Both U.S. and European regulatory authorities have provided Acurx with approval to proceed with international Phase 3 studies.
- The company’s full-year 2025 net loss decreased to $8.0 million from $14.1 million, while cash reserves grew to $7.6 million.
Acurx Pharmaceuticals (ACXP) delivered one of the standout performances in the biotech sector this year. Shares surged more than 218% across five trading days following the company’s disclosure of a new clinical trial initiative for ibezapolstat, its leading antibiotic candidate designed to combat C. difficile infection.
Acurx Pharmaceuticals, Inc., ACXP
The majority of the rally followed Monday’s announcement that established the groundwork for Phase 3 development. Friday morning brought an additional 3.59% gain in pre-market activity after the company released its Q4 earnings figures.
C. difficile, commonly called CDI, represents a bacterial infection affecting the gastrointestinal tract with a high propensity for recurrence. Patients experiencing three or more episodes within a year face limited therapeutic options and persistent challenges with recurring infections.
Phase 2 results for ibezapolstat provided compelling evidence for market participants. The compound achieved a 96% clinical cure rate across 26 patients diagnosed with acute CDI. The more remarkable outcome — every patient who achieved clinical cure remained infection-free throughout the entire follow-up duration.
This dual capability of treating active infection while preventing subsequent episodes represents what Acurx considers ibezapolstat’s key differentiator. Existing treatments typically address the immediate infection while failing to prevent future recurrences.
Acurx plans to initiate a 20-patient open-label pilot trial concentrating exclusively on individuals with multiply-recurrent CDI — specifically those who have experienced a minimum of three episodes within the preceding 12 months. Data gathered from this pilot study will inform the architecture of the comprehensive Phase 3 registration trial.
Regulatory Approvals Secured
Among the week’s significant developments was verification that regulatory bodies in both the United States and Europe have provided Acurx with defined pathways to commence international Phase 3 investigations. This type of bilateral regulatory guidance eliminates substantial uncertainty for a small-capitalization biotechnology company.
This approval structure indicates the company’s strategy extends beyond domestic trials — the framework incorporates international dimensions from inception.
During February 2026, Acurx obtained a new patent covering its Pol IIIC inhibitors, securing intellectual property protection until December 2039. This extended timeframe provides substantial market exclusivity should the drug achieve commercialization.
Q4 Financial Performance: Improved Cost Management
Regarding financial metrics, Acurx disclosed a Q4 2025 loss of $5.32 per share, exceeding the $3.29 loss recorded in Q4 2024. The annual overview presents a more favorable trajectory.
For the complete 2025 fiscal year, net losses totaled $8.0 million versus $14.1 million in 2024 — representing a substantial improvement. Research and development expenditures declined to $0.3 million from $0.8 million, while general and administrative costs decreased to $1.3 million from $2.0 million.
Liquidity metrics also strengthened. Acurx concluded the period ending December 31, 2025 with $7.6 million in cash reserves, an increase from $3.7 million the previous year. This enhanced financial position provides greater stability as the company enters its trial program.
Current Wall Street consensus includes two analysts rating ACXP as a Moderate Buy, establishing an average 12-month price target of $17.50.
Following Friday morning’s earnings disclosure, shares traded with a 3.59% pre-market increase after confirmation of the new rCDI trial commencement.
